ClinicalTrials.gg
CompletedNCT03538756Updated Dec 22, 2022Results posted

walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis

An interventional study of Walkasins in Sensory Peripheral Neuropathy, Balance; Distorted and Sensation Disorders, sponsored by RxFunction Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-12-22.

Sponsored by RxFunction Inc. · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Sensation Disorders with a site in United States — 8 open to participants now, 11 under way, 2 of them phase 3. Sensation Disorders · United States.

Enrollment
4th of 19
69 · median 30
Started
2018
the only one that year
No phase
12 of 26
3 open now
Registered
8th of 26
by date

Among the 26 studies in Sensation Disorders with a site in United States, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2018, is one of 12 with no phase, and was the 8th registered.

Sensation Disorders

87 studies on the registry are indexed under Sensation Disorders; 23 are open to participants now.

Browse Sensation Disorders studies →

Open to participants now

8 of the 26 studies in Sensation Disorders with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Sensation Disorders studies recruiting now, 5 (33%) set no upper age limit and 6 (40%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Sensation Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the long-term effects of Walkasins® use on clinical and subject-reported outcomes of balance and gait function, quality of life, physical activity/participation, pain, and medication use in persons with peripheral neuropathy who experience balance problems.

Read the detailed description

The main objectives of this single-arm study are to show a long-term (10 weeks), sustained improvement in Functional Gait Assessment (FGA) score >4 following Walkasins use as compared to participants' initial baseline assessments and to examine a potential relationship between initial baseline assessment data and long-term outcomes. The previous finding of a short-term FGA change >4 during Walkasins use (NCT02115633) justifies a pre-post study design to investigate the long-term effects of Walkasins use. Although the primary timeframe for the primary endpoint is 10 weeks, participants will return for follow-up visits at 26 weeks and 52 weeks of Walkasins use.

The investigators also intend to extend their observations of the short-term effects of Walkasins by replicating the randomized cross-over design of a previous short-term study. (The randomized cross-over replication will occur only during the baseline visit. The long-term study consists of a single arm.) This study may help to further refine the prescription criteria for Walkasins and determine whether or not the presence of a short-term response is indicative of long-term improvements.

A subset of 10 participants at the Harvard Medical School site will be enrolled in a pilot study to investigate possible structural and functional changes in cortical areas of the brain related to somatosensory connectivity using magnetic resonance imaging (MRI). Structural as well as functional MRI scans will be acquired at baseline and after 26 weeks of daily Walkasins use. An exploratory analysis of MRI data will be performed and related to functional clinical outcomes associated with Walkasins use over the same time period.

03

Conditions studied

  • Sensory Peripheral Neuropathy
  • Balance; Distorted
  • Sensation Disorders

Keywords

  • Balance
  • Peripheral Neuropathy
  • Neuropathy
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-90 years, male or female
  • Formal diagnosis of sensory peripheral neuropathy prior to participating in the study
  • Self-reported balance problems
  • Ability for transfers or ambulation on level surfaces at fixed cadence as assessed by the physical therapist during the FGA
  • FGA \<23, the cut-off score for high fall-risk
  • Ability to understand and provide
  • Foot size that allows Walkasins® to function appropriately
  • Must be able to complete all functional outcome measures without the use of an assistive device

Exclusion criteria

Exclusion Criteria:

  • Inability to perceive vibration from Walkasins leg unit
  • Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins
  • Acute thrombophlebitis including deep vein thrombosis
  • Untreated lymphedema
  • Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use
  • Untreated fractures in the foot and ankle
  • Severe peripheral vascular disease
  • Musculoskeletal or other neurological conditions that prohibit use of Walkasins as determined by clinician
  • Weighs more than 300 pounds
  • Plans to begin balance physical therapy (PT) during the first ten weeks of the clinical trial (Ongoing or previous balance PT is not an exclusionary criterion.)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Baseline Group A--Walkasins On Then Off

    Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off. After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits

    Device: Walkasins

  • Experimental
    Baseline Group B--Walkasins Off Then On

    Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on. After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits.

    Device: Walkasins

  • Experimental
    Single Arm Long-Term Follow-up

    During the baseline visit, participants were randomized to two groups that applied to the first visit only. After the baseline visit, community-dwelling participants received Walkasins to wear over the next 52 weeks. They returned for follow-up visits at weeks 2, 6, 10, 26, and 52, during which they repeated the functional measures while wearing their Walkasins and responded to the questionnaires. Between weeks 10 and 26 and 26 and 52, they were contacted periodically to remind them of study requirements and to collect follow-up information regarding health changes, adverse events, pain scores, device usage, and device functioning. Note: Due to COVID-19 disruptions, some participants were not able to return for all in-person follow-up visits. They completed the patient-reported outcome measures via telephone visits.

    Device: Walkasins

Interventions

  • DeviceWalkasins

    Walkasins® consist of two parts for each leg: the Haptic Module (leg unit) and the Receptor Sole (foot pad). The Haptic Module wraps around the lower leg of the user and contains electronics for reading Receptor Sole pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.

06

What researchers measure

Primary outcomes

  1. Functional Gait Assessment

    The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability. (Participants scoring 23 or higher on the baseline FGA were not included in this study because their peripheral neuropathy was not yet affecting their gait/balance significantly.)

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

Secondary outcomes

  1. 10-Meter Walk Test

    Gait speed (10-meter walk, timing the middle 6 meters) is assessed under two conditions: Participants are instructed (1) to walk at normal speed and (2) to walk as fast as they can. Higher numbers indicate faster speeds (i.e., more meters per second).

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  2. Timed Up and Go Test (TUG)

    The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  3. Four-Stage Balance Test

    The 4-Stage Balance Test is part of the Centers for Disease Control's recommended test protocol for balance function. It includes four gradually more challenging postures the subject is exposed to: (1) Stand with feet side by side. (2) Stand with feet in semi-tandem stance. (3) Stand with feet in tandem stance. (4) Stand on one leg. Participants pass each level if they can hold the stance for 10 seconds and then move on to the next stance. If they cannot hold the stance, the test ends. Higher times indicate better balance than lower times.

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  4. Activities-specific Balance Confidence (ABC) Scale

    Powell and Myers (1995) developed the Activities-specific Balance Confidence (ABC) Scale to detect levels of balance confidence in elderly persons. The ABC scale is a one-page questionnaire that asks questions about balance confidence when performing 16 different tasks. The items are rated on a scale of 0 to 100; a score of 0 indicates no confidence and a score of 100 indicates complete confidence when performing the task. The overall score is calculated by adding the individual items then dividing by the total number of items (16). The higher the score, the greater the person's balance confidence; thus, higher scores indicate that subjects are more confident of their balance.

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  5. Vestibular Activities of Daily Living Scale (VADL)

    The Vestibular Activities of Daily Living Scale (VADL) is a self-reported questionnaire that was developed to assess self-perceived disability in individuals with vestibular impairment. It evaluates the effects of vertigo and balance disorders on independence in 28 activities of daily living. Participants selected a number ranging from 1 = "Independent" to 10 = "Too Difficult, No Longer Perform." The scores on the 28 activities were averaged. The higher the score (up to 10), the greater is the person's self-perceived disability (i.e., the person feels less independence in activities of daily living). Lower averages of the 28 items indicate greater independence in activities of daily living (e.g., a healthy adult's VADL score most likely would be between 1.0 and 2.0).

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  6. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a nine-question tool for assessing depression and emotional well-being. Participants rate nine areas on a 0 to 3 scale in response to the question, "Over the last 2 weeks, how often have you been bothered by any of the following problems?" The rating scale is as follows: 0 = "Not at All," 1 = "Several Days," 2 = "More Than Half the Days," and 3 = "Nearly Every Day." A PHQ-9 total score of 0-4 points indicates "normal" or minimal depression. Scores between 5-9 points indicate mild depression; 10-14 points, moderate depression; 15-19 points, moderately severe depression; and 20 or more points, severe depression. (The minimum score on the PHQ-9 is 0; the maximum score is 27.) In short, lower scores indicate less depression.

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  7. Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b measures the self-reported consequences of pain on relevant aspects of a person's life over the past 7 days and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). Higher scores (i.e., those greater than 50, the mean) indicate that the participants perceive their pain as interfering in their daily lives more than average; lower scores (i.e., those less than 50, the mean) indicate that the participants perceive their pain as interfering less than average in their daily lives, which would be considered a better outcome.

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  8. PROMIS Pain Intensity Form 1a

    The PROMIS Pain Intensity Form 1a instrument asks participants to rate the intensity of their pain on average over the previous 7 days. It is universal rather than disease specific. The higher the score on a scale of 0 ("no pain") to 10 ("worst pain imaginable), the more intense is the person's perception of pain; lower scores indicate less intense perception of pain, a better outcome.

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  9. PROMIS Ability to Participate Short Form 8a

    The PROMIS Ability to Participate in Social Roles and Activities assesses the participants' perceived ability to perform their usual social roles and activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., greater than 50, the mean) indicates participants perceive they have a better ability to participate in their roles and activities (i.e., a better outcome).

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  10. PROMIS Satisfaction With Participation in Social Roles Short Form 8a

    The PROMIS Satisfaction with Social Roles and Activities items assess satisfaction with performing one's usual social roles and activities (e.g., "I am satisfied with my ability to participate in family activities"). PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., those greater than 50, the mean) indicates the respondents' greater satisfaction in regard to their ability to participate in their roles and activities (i.e., a better outcome).

    Time frame: Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52

  11. Falls

    Subjects were asked about the number of times they have fallen in the past 6 and 12 months and whether they incurred an injury from falling. (For this study, the researchers used the World Health Organization's definition of a fall: "an event which results in a person coming to rest inadvertently on the ground or floor or other lower level.") These data were compared to falls during their participation in the trial as tracked with a calendar and reported as adverse events. Falls data were monitored as overall number of falls and fallers pre-and post-study participation as well as the number of falls/1000 patient days. A lower number indicates fewer falls over 26 weeks (6 months).

    Time frame: Baseline and 26 Weeks

07

Results

Posted Dec 22, 2022
Limitations and caveats
The main limitations of this trial were the following: (1) It was not blinded, and it lacked a control group and a placebo treatment. (2) We enrolled a greater percentage of males than females. (3) Lockdowns at the study sites due to COVID-19 caused significant disruptions to data collection for the functional measures. Some participants also indicated that COVID-19 impacted their daily activities, which, in turn, affected the amount of time they used the device.

Participant flow

Participants were recruited at five sites through various methods, including physician referral and recruitment posters. The first participant was enrolled on October 22, 2018, and the last participant was enrolled in April 2021.

Baseline Cross-over
Participant flow — Baseline Cross-over
MilestoneBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Started36330
Completed36330
Not completed000
Long-Term Follow-up
Participant flow — Long-Term Follow-up
MilestoneBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Started0069
Completed0036
Not completed0033
Withdrew: Adverse event006
Withdrew: Death001
Withdrew: Withdrawal by subject005
Withdrew: Covid-19 disruptions at sites0013
Withdrew: Device dissatisfaction008

Outcome measures

PrimaryFunctional Gait Assessment

The Functional Gait Assessment (FGA) is a 10-item scale that measures postural stability while individuals perform walking tasks that are scored from 0 to 3 (3 = normal, 2 = mild impairment, 1 = moderate impairment, 0 = severe impairment). Scores range from a minimum of 0 to a maximum of 30. Higher scores indicate better postural stability. (Participants scoring 23 or higher on the baseline FGA were not included in this study because their peripheral neuropathy was not yet affecting their gait/balance significantly.)

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · score on a scale
Functional Gait Assessment
score on a scaleBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline14.8 ± 4.114.8 ± 4.114.8 ± 4.1
Baseline Crossover--Walkasins ON17.0 ± 4.518.2 ± 3.8—
Baseline Crossover--Walkasins OFF17.14 ± 4.516.3 ± 3.9—
Week 2——17.9 ± 4.7
Week 6——18.2 ± 4.4
Week 10——19.2 ± 5
Week 26——19.1 ± 4
Week 52——20.7 ± 5.3
Secondary10-Meter Walk Test

Gait speed (10-meter walk, timing the middle 6 meters) is assessed under two conditions: Participants are instructed (1) to walk at normal speed and (2) to walk as fast as they can. Higher numbers indicate faster speeds (i.e., more meters per second).

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · Meters/Second
10-Meter Walk Test
Meters/SecondBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline Normal Gait Speed0.90 ± 0.290.85 ± 0.190.88 ± 0.25
Baseline Crossover--Walkasins ON0.92 ± 0.280.91 ± 0.19—
Baseline Crossover--Walkasins OFF0.95 ± 0.290.90 ± 0.17—
Week 2 Normal Gait Speed——0.94 ± 0.28
Week 6 Normal Gait Speed——0.95 ± 0.27
Week 10 Normal Gait Speed——0.97 ± 0.26
Week 26 Normal Gait Speed——0.97 ± 0.28
Week 52 Normal Gait Speed——1.02 ± 0.30
SecondaryTimed Up and Go Test (TUG)

The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · Seconds
Timed Up and Go Test (TUG)
SecondsBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline13.9 ± 6.213.5 ± 4.513.7 ± 5.5
Baseline Crossover--Walkasins ON13.7 ± 5.212.8 ± 3.9—
Baseline Crossover--Walkasins OFF13.2 ± 5.812.7 ± 3.7—
Week 2——12.8 ± 4.2
Week 6——12.4 ± 4.2
Week 10——12.1 ± 3.6
Week 26——12.3 ± 3.4
Week 52——12.2 ± 3.7
SecondaryFour-Stage Balance Test

The 4-Stage Balance Test is part of the Centers for Disease Control's recommended test protocol for balance function. It includes four gradually more challenging postures the subject is exposed to: (1) Stand with feet side by side. (2) Stand with feet in semi-tandem stance. (3) Stand with feet in tandem stance. (4) Stand on one leg. Participants pass each level if they can hold the stance for 10 seconds and then move on to the next stance. If they cannot hold the stance, the test ends. Higher times indicate better balance than lower times.

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · Seconds
Four-Stage Balance Test
SecondsBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline24.2 ± 6.926.5 ± 8.025.3 ± 7.5
Baseline Crossover--Walkasins ON25.4 ± 7.526.6 ± 6.4—
Baseline Crossover--Walkasins OFF26.0 ± 6.927.7 ± 6.6—
Week 2——27.1 ± 8.0
Week 6——27.4 ± 7.4
Week 10——27.3 ± 6.9
Week 26——28.4 ± 5.6
Week 52——31.1 ± 6.8
SecondaryActivities-specific Balance Confidence (ABC) Scale

Powell and Myers (1995) developed the Activities-specific Balance Confidence (ABC) Scale to detect levels of balance confidence in elderly persons. The ABC scale is a one-page questionnaire that asks questions about balance confidence when performing 16 different tasks. The items are rated on a scale of 0 to 100; a score of 0 indicates no confidence and a score of 100 indicates complete confidence when performing the task. The overall score is calculated by adding the individual items then dividing by the total number of items (16). The higher the score, the greater the person's balance confidence; thus, higher scores indicate that subjects are more confident of their balance.

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · score on a scale
Activities-specific Balance Confidence (ABC) Scale
score on a scaleBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline Crossover58.2 ± 17.361.2 ± 16.259.6 ± 16.7
Week 2——62.5 ± 15.2
Week 6——62.3 ± 16.9
Week 10——63.6 ± 14.8
Week 26——62.1 ± 16.5
Week 52——65.2 ± 16.7
SecondaryVestibular Activities of Daily Living Scale (VADL)

The Vestibular Activities of Daily Living Scale (VADL) is a self-reported questionnaire that was developed to assess self-perceived disability in individuals with vestibular impairment. It evaluates the effects of vertigo and balance disorders on independence in 28 activities of daily living. Participants selected a number ranging from 1 = "Independent" to 10 = "Too Difficult, No Longer Perform." The scores on the 28 activities were averaged. The higher the score (up to 10), the greater is the person's self-perceived disability (i.e., the person feels less independence in activities of daily living). Lower averages of the 28 items indicate greater independence in activities of daily living (e.g., a healthy adult's VADL score most likely would be between 1.0 and 2.0).

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · score on a scale
Vestibular Activities of Daily Living Scale (VADL)
score on a scaleBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline3.97 ± 1.133.82 ± 1.153.89 ± 1.14
Week 2——3.49 ± 1.1
Week 6——3.66 ± 1.09
Week 10——3.78 ± 1.03
Week 26——3.66 ± 1.22
Week 52——3.62 ± 1.12
SecondaryPatient Health Questionnaire-9 (PHQ-9)

The PHQ-9 is a nine-question tool for assessing depression and emotional well-being. Participants rate nine areas on a 0 to 3 scale in response to the question, "Over the last 2 weeks, how often have you been bothered by any of the following problems?" The rating scale is as follows: 0 = "Not at All," 1 = "Several Days," 2 = "More Than Half the Days," and 3 = "Nearly Every Day." A PHQ-9 total score of 0-4 points indicates "normal" or minimal depression. Scores between 5-9 points indicate mild depression; 10-14 points, moderate depression; 15-19 points, moderately severe depression; and 20 or more points, severe depression. (The minimum score on the PHQ-9 is 0; the maximum score is 27.) In short, lower scores indicate less depression.

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · score on a scale
Patient Health Questionnaire-9 (PHQ-9)
score on a scaleBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline5.19 ± 4.634.30 ± 3.534.77 ± 4.13
Week 2——3.97 ± 3.96
Week 6——4.12 ± 4.16
Week 10——4.18 ± 4.62
Week 26——4.19 ± 4.03
Week 52——4.83 ± 4.95
SecondaryPatient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b

The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b measures the self-reported consequences of pain on relevant aspects of a person's life over the past 7 days and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). Higher scores (i.e., those greater than 50, the mean) indicate that the participants perceive their pain as interfering in their daily lives more than average; lower scores (i.e., those less than 50, the mean) indicate that the participants perceive their pain as interfering less than average in their daily lives, which would be considered a better outcome.

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · T-score
Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference Short Form 6b
T-scoreBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline52.6 ± 8.350.1 ± 8.751.4 ± 8.5
Week 2——51.7 ± 7.8
Week 6——51.1 ± 8.9
Week 10——52.2 ± 8.5
Week 26——51.2 ± 8.5
Week 52——52.8 ± 9.1
SecondaryPROMIS Pain Intensity Form 1a

The PROMIS Pain Intensity Form 1a instrument asks participants to rate the intensity of their pain on average over the previous 7 days. It is universal rather than disease specific. The higher the score on a scale of 0 ("no pain") to 10 ("worst pain imaginable), the more intense is the person's perception of pain; lower scores indicate less intense perception of pain, a better outcome.

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · score on a scale
PROMIS Pain Intensity Form 1a
score on a scaleBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline3.2 ± 2.62.4 ± 2.02.8 ± 2.3
Week 2——2.6 ± 2.1
Week 6——2.8 ± 2.5
Week 10——2.7 ± 2.4
Week 26——2.7 ± 2.1
Week 52——3.2 ± 2.9
SecondaryPROMIS Ability to Participate Short Form 8a

The PROMIS Ability to Participate in Social Roles and Activities assesses the participants' perceived ability to perform their usual social roles and activities. PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., greater than 50, the mean) indicates participants perceive they have a better ability to participate in their roles and activities (i.e., a better outcome).

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · score on a scale
PROMIS Ability to Participate Short Form 8a
score on a scaleBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline48.8 ± 7.750.7 ± 8.749.7 ± 8.2
Week 2——51.1 ± 7.5
Week 6——50.9 ± 7.3
Week 10——51.1 ± 7.9
Week 26——52.0 ± 8.1
Week 52——48.7 ± 7.9
SecondaryPROMIS Satisfaction With Participation in Social Roles Short Form 8a

The PROMIS Satisfaction with Social Roles and Activities items assess satisfaction with performing one's usual social roles and activities (e.g., "I am satisfied with my ability to participate in family activities"). PROMIS measures are scored on the T-score metric (mean = 50, standard deviation = 10). A higher score (i.e., those greater than 50, the mean) indicates the respondents' greater satisfaction in regard to their ability to participate in their roles and activities (i.e., a better outcome).

Time frame:
Baseline, Week 2, Week 6, Week 10 (Primary Endpoint), Week 26, and Week 52
Reported as:
Mean · score on a scale
PROMIS Satisfaction With Participation in Social Roles Short Form 8a
score on a scaleBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Baseline47.7 ± 6.349.9 ± 8.148.7 ± 7.3
Week 2——49.2 ± 7.5
Week 6——50.1 ± 7.9
Week 10——50.4 ± 8.4
Week 26——51.0 ± 8.3
Week 52——49.4 ± 8.5
SecondaryFalls

Subjects were asked about the number of times they have fallen in the past 6 and 12 months and whether they incurred an injury from falling. (For this study, the researchers used the World Health Organization's definition of a fall: "an event which results in a person coming to rest inadvertently on the ground or floor or other lower level.") These data were compared to falls during their participation in the trial as tracked with a calendar and reported as adverse events. Falls data were monitored as overall number of falls and fallers pre-and post-study participation as well as the number of falls/1000 patient days. A lower number indicates fewer falls over 26 weeks (6 months).

Time frame:
Baseline and 26 Weeks
Reported as:
Number · Number of Participant Falls
Falls
Number of Participant FallsBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Pre-Study/Baseline——53
Week 26——39

Adverse events

Collected over Adverse events were collected during the period of each subject's participation, a maximum of 52 weeks per participant. (The average duration of subjects' participation in the study was 271 days.). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baseline Cross-over Group A--Walkasins ON Then OFF———
Baseline Cross-over Group B--Walkasins OFF Then ON———
Single-Arm Long-Term Follow-up (Walkasins ON)1/69 (1.4%)10/69 (14.5%)24/69 (34.8%)
Most frequent serious events
Most frequent serious events
EventBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
HospitalizationsCardiac disorders——2/69
HospitalizationsRespiratory, thoracic and mediastinal disorders——2/69
HospitalizationsInjury, poisoning and procedural complications——2/69
HospitalizationBlood and lymphatic system disorders——1/69
HospitalizationCardiac disorders——1/69
HospitalizationBlood and lymphatic system disorders——1/69
HospitalizationPsychiatric disorders——1/69
HospitalizationSurgical and medical procedures——1/69
Most frequent other events
Most frequent other events
EventBaseline Cross-over Group A--Walkasins ON Then OFFBaseline Cross-over Group B--Walkasins OFF Then ONSingle-Arm Long-Term Follow-up (Walkasins ON)
Falls with Minor InjuriesGeneral disorders——24/69
Skin IrritationSkin and subcutaneous tissue disorders——9/69
Knee PainMusculoskeletal and connective tissue disorders——5/69
Hip PainMusculoskeletal and connective tissue disorders——4/69

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Single-Arm Long-Term Use
<=18 years0
Between 18 and 65 years7
>=65 years62
Sex: Female, Male
Sex: Female, Male(Participants)Single-Arm Long-Term Use
Female17
Male52
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single-Arm Long-Term Use
Hispanic or Latino3
Not Hispanic or Latino65
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single-Arm Long-Term Use
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American2
White66
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Single-Arm Long-Term Use
United States69
Weight (kg)
Weight (kg)(Kilograms)Single-Arm Long-Term Use
Mean89.7 ± 18.2
08

Study locations

5 sites
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21287, United States
  • Marcus Institute for Aging Research, Harvard Medical School
    Boston, Massachusetts 02131, United States
  • Minneapolis VA Health Care System
    Minneapolis, Minnesota 55417, United States
  • Fairview Health Services
    Saint Paul, Minnesota 55114, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Oddsson LIE, Bisson T, Cohen HS, Iloputaife I, Jacobs L, Kung D, Lipsitz LA, Manor B, McCracken P, Rumsey Y, Wrisley DM, Koehler-McNicholas SR. Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk-The walk2Wellness trial. Front Aging Neurosci. 2022 Sep 20;14:931048. doi: 10.3389/fnagi.2022.931048. eCollection 2022. PubMed 36204554 ↗
  • Oddsson LIE, Bisson T, Cohen HS, Jacobs L, Khoshnoodi M, Kung D, Lipsitz LA, Manor B, McCracken P, Rumsey Y, Wrisley DM, Koehler-McNicholas SR. The Effects of a Wearable Sensory Prosthesis on Gait and Balance Function After 10 Weeks of Use in Persons With Peripheral Neuropathy and High Fall Risk - The walk2Wellness Trial. Front Aging Neurosci. 2020 Nov 9;12:592751. doi: 10.3389/fnagi.2020.592751. eCollection 2020. PubMed 33240077 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Dec 2021, 38 months.

Results were first posted in Dec 2022, 11 months after primary completion.

Of 32 interventional studies with no phase under Sensation Disorders, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 45. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
May 29, 2018
StartActual
Oct 22, 2018
Primary completionActual
Dec 31, 2021
CompletionActual
Dec 31, 2021
Results first posted
Dec 22, 2022
Last update
Dec 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03538756
Lead sponsor
RxFunction Inc.
Responsible party
Sponsor
First posted
May 29, 2018
Start date
Oct 22, 2018
Primary completion
Dec 31, 2021
Completion
Dec 31, 2021
Results posted
Dec 22, 2022
Last update
Dec 22, 2022

Study contacts

Lars Oddsson, PhD
study director · RxFunction Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion